Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 06 Sep 2021
UK MHRA grants GenSight Biologics’ Lumevoq ophthalmic gene therapy Promising Innovative Medicine Designation
6 September 2021 - GenSight Biologics today announced that its gene therapy Lumevoq has been granted Promising Innovative Medicine designation by ...
Posted by Michael Wonder on 06 Sep 2021
EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty
6 September 2021 - EMA has started evaluating an application for the use of a booster dose of Comirnaty to be ...
Posted by Michael Wonder on 06 Sep 2021
Leap forward for patients accessing medicines
7 September 2021 - Medicines Australia has secured a 5 year strategic agreement with the Federal Government, centered on earlier ...
Posted by Michael Wonder on 06 Sep 2021
Health economic assessment of Sarclisa in multiple myeloma
6 September 2021 - TLV has produced a health economic assessment for the regions for the drug Sarclisa (isatuximab) in combination ...
Posted by Michael Wonder on 06 Sep 2021
Democrats’ plans to introduce prescription drug pricing reform face formidable obstacles
6 September 2021 - For years, reducing prescription drug prices has been a policy goal of (mostly Democratic) legislators at the ...
Posted by Michael Wonder on 06 Sep 2021
Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
6 September 2021 - Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its ...
Posted by Michael Wonder on 06 Sep 2021
Statement on Moderna COVID-19 vaccine
6 September 2021 - Medicines Australia welcomes the TGA provisional approval for the COVID-19 vaccine, Spikevax (Moderna) for Australia. The ...
Posted by Michael Wonder on 06 Sep 2021
Four million Pfizer doses arrive to super-charge vaccine roll out
6 September 2021 - Four million extra Pfizer-BioNTech (Pfizer) vaccine doses will begin arriving in Australia in days following a historic ...
Posted by Michael Wonder on 06 Sep 2021
New treatment option for schizophrenia Reagila listed on PBS
6 September 2021 - Adults living with schizophrenia will have access to a new treatment option with Reagila (cariprazine), reimbursed ...
Posted by Michael Wonder on 06 Sep 2021
New Zealand’s tocilizumab supply to be paused
6 September 2021 - PHARMAC has today announced that Roche, the global pharmaceutical company which provides tocilizumab, will not provide New ...
Posted by Michael Wonder on 05 Sep 2021
CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC
2 September 2021 - Sugemalimab becomes the world’s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival in patients with stage ...
Posted by Michael Wonder on 05 Sep 2021
America desperately needs a much better FDA
2 September 2021 - In the early 1960s, an unflappable FDA scientist named Frances Kelsey spared the nation from the horrors ...
Posted by Michael Wonder on 05 Sep 2021
Moderna announces submission of data to European Medicines Agency for its COVID-19 vaccine booster
3 September 2021 - mRNA-1273 at 50 µg dose level induced robust antibody responses of more than 40 times against ...
Posted by Michael Wonder on 04 Sep 2021
GSK’s shingles vaccine Shingrix gains UK license
2 September 2021 - GlaxoSmithKline's Shingrix has been licensed in the UK for the prevention of shingles in adults aged ...
Posted by Michael Wonder on 04 Sep 2021
COVID-19 vaccine: Spikevax (elasomeran)
4 September 2021 - On 3 September 2021, the TGA granted provisional approval to Moderna Australia for the use of ...